1673 related articles for article (PubMed ID: 15692967)
1. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
[TBL] [Abstract][Full Text] [Related]
2. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.
Khanna D; Yan X; Tashkin DP; Furst DE; Elashoff R; Roth MD; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M; Clements PJ;
Arthritis Rheum; 2007 May; 56(5):1676-84. PubMed ID: 17469162
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
4. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
Khanna D; Furst DE; Clements PJ; Park GS; Hays RD; Yoon J; Korn JH; Merkel PA; Rothfield N; Wigley FM; Moreland LW; Silver R; Steen VD; Weisman M; Mayes MD; Collier DH; Medsger TA; Seibold JR; ;
J Rheumatol; 2005 May; 32(5):832-40. PubMed ID: 15868618
[TBL] [Abstract][Full Text] [Related]
5. The relationship of dyspnoea to function and quality of life in systemic sclerosis.
Baron M; Sutton E; Hudson M; Thombs B; Markland J; Pope J; Robinson D; Jones N; Docherty P; Abu-Hakima M; LeClercq S; Smith D; Mathieu JP
Ann Rheum Dis; 2008 May; 67(5):644-50. PubMed ID: 17728334
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide versus placebo in scleroderma lung disease.
Tashkin DP; Elashoff R; Clements PJ; Goldin J; Roth MD; Furst DE; Arriola E; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M;
N Engl J Med; 2006 Jun; 354(25):2655-66. PubMed ID: 16790698
[TBL] [Abstract][Full Text] [Related]
7. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
8. Impact of pain in health related quality of life of patients with systemic sclerosis.
Georges C; Chassany O; Toledano C; Mouthon L; Tiev K; Meyer O; Ilie D; Rambeloarisoa J; Marjanovic Z; Cabane J; Sereni D; Pouchot J; Farge D
Rheumatology (Oxford); 2006 Oct; 45(10):1298-302. PubMed ID: 16754629
[TBL] [Abstract][Full Text] [Related]
9. Health status, dyspnea, lung function and exercise capacity in patients with chronic obstructive pulmonary disease.
Stavem K; Boe J; Erikssen J
Int J Tuberc Lung Dis; 1999 Oct; 3(10):920-6. PubMed ID: 10524591
[TBL] [Abstract][Full Text] [Related]
10. [The evaluation of dyspnea and quality of life in COPD].
Demir G; Akkoca O; Doğan R; Saryal S; Karabiyikoğlu G
Tuberk Toraks; 2003; 51(4):365-72. PubMed ID: 15143383
[TBL] [Abstract][Full Text] [Related]
11. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
[TBL] [Abstract][Full Text] [Related]
12. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis.
Colaci M; Sebastiani M; Giuggioli D; Manfredi A; Spagnolo P; Luppi F; Richeldi L; Ferri C
Scand J Rheumatol; 2010 Mar; 39(2):155-9. PubMed ID: 20059446
[TBL] [Abstract][Full Text] [Related]
13. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
Garin MC; Highland KB; Silver RM; Strange C
J Rheumatol; 2009 Feb; 36(2):330-6. PubMed ID: 19208563
[TBL] [Abstract][Full Text] [Related]
14. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline.
Plastiras SC; Karadimitrakis SP; Ziakas PD; Vlachoyiannopoulos PG; Moutsopoulos HM; Tzelepis GE
Arthritis Rheum; 2006 Aug; 55(4):598-602. PubMed ID: 16874782
[TBL] [Abstract][Full Text] [Related]
15. Validity of the Saint George's Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis.
Beretta L; Santaniello A; Lemos A; Masciocchi M; Scorza R
Rheumatology (Oxford); 2007 Feb; 46(2):296-301. PubMed ID: 16877463
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the functional parameters in scleroderma cases with pulmonary involvement.
Celebi Sözener Z; Karabıyıkoğlu G; Düzgün N
Tuberk Toraks; 2010; 58(3):235-41. PubMed ID: 21038133
[TBL] [Abstract][Full Text] [Related]
17. Computer-Aided Tomographic Analysis of Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc). Correlation with Pulmonary Physiologic Tests and Patient-Centred Measures of Perceived Dyspnea and Functional Disability.
Salaffi F; Carotti M; Di Donato E; Di Carlo M; Ceccarelli L; Giuseppetti G
PLoS One; 2016; 11(3):e0149240. PubMed ID: 26930658
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.
Várai G; Earle L; Jimenez SA; Steiner RM; Varga J
J Rheumatol; 1998 Jul; 25(7):1325-9. PubMed ID: 9676764
[TBL] [Abstract][Full Text] [Related]
19. The six-minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease.
Wilsher M; Good N; Hopkins R; Young P; Milne D; Gibson A; Suppiah R; Ly J; Doughty R; Dalbeth N
Respirology; 2012 May; 17(4):647-52. PubMed ID: 22256786
[TBL] [Abstract][Full Text] [Related]
20. [The value of SF-36 questionnaire for the measurement of life quality in chronic obstructive pulmonary disease].
Soyyiğit S; Erk M; Güler N; Kilinç G
Tuberk Toraks; 2006; 54(3):259-66. PubMed ID: 17001544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
